SCHEDULE 13G/A: ADAR1 Capital Management and Affiliates Report 3.18% Passive Stake in ZURA BIO LIMITED
Beneficial Ownership Report
ADAR1 Capital Management, along with its general partner and manager Daniel Schneeberger, has filed an amended Schedule 13G reporting a combined beneficial ownership of 3.18% in ZURA BIO LIMITED's Class A Ordinary Shares as of December 31, 2024.
Summary
- ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have filed an amended Schedule 13G (Amendment No. 1) concerning their beneficial ownership in ZURA BIO LIMITED.
- ADAR1 Capital Management, LLC and Daniel Schneeberger each beneficially own 2,077,251 Class A Ordinary Shares of ZURA BIO LIMITED, which represents 3.18% of the outstanding shares.
- ADAR1 Capital Management GP, LLC beneficially owns 1,578,787 Class A Ordinary Shares, representing 2.42% of the outstanding shares.
- The beneficial ownership for ADAR1 Capital Management, LLC and Daniel Schneeberger includes 1,578,787 shares held by ADAR1 Partners, LP, and 498,464 shares held by Spearhead Insurance Solutions IDF, LLC.
- ADAR1 Capital Management, LLC acts as the investment manager for ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
- ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP.
- Daniel Schneeberger is the manager of both ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC.
- The reported percentages are based on 65,293,530 Class A Ordinary Shares of ZURA BIO LIMITED outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine Schedule 13G filing disclosing beneficial ownership, which is purely factual and does not convey positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment manager and its affiliates in a publicly traded biotechnology company, ZURA BIO LIMITED. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of an investment firm holding a passive stake.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors and their affiliates.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which 65,293,530 Class A Ordinary Shares of ZURA BIO LIMITED were reported outstanding in the Issuer's Quarterly Report on Form 10-Q. |
| 2024-11-07 | Date ZURA BIO LIMITED's Quarterly Report on Form 10-Q for the period ended September 30, 2024, was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 1 was signed by the Reporting Persons. |
Keywords
ZURA BIO LIMITED, ADAR1 Capital Management, Daniel Schneeberger, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Investment Management, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.